Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 890 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast - Male Clear all
Completed Phase 2 Interventional

Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

NCT01163552
View directory record Official record
Conditions
Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer, Uterine Cancer, Renal Cell Cancer, Thymic Cancer
Interventions
Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Nov 7, 2026, 1:57 PM EST
Completed Phase 1 Interventional

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

NCT00003038
View directory record Official record
Conditions
Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, suramin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Nov 7, 2026, 1:57 PM EST
Completed Phase 3 Interventional Results available

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

NCT00869206
View directory record Official record
Conditions
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary Complications
Interventions
zoledronic acid
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
503
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Castro Valley, California + 353 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Nov 7, 2026, 1:57 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

NCT04354064
View directory record Official record
Conditions
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 7, 2026, 1:57 PM EST
Terminated Phase 2 Interventional Results available

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

NCT01147016
View directory record Official record
Conditions
Breast Cancer
Interventions
HER2Bi-armed activated T cells, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, laboratory biomarker analysis, neoadjuvant therapy, therapeutic conventional surgery
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Nov 7, 2026, 1:57 PM EST
Completed Phase 1 Interventional

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

NCT02890069
View directory record Official record
Conditions
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Interventions
PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Nov 7, 2026, 1:57 PM EST
Terminated Phase 3 Interventional Results available

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT04588246
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 7, 2026, 1:57 PM EST
Terminated Not applicable Interventional

Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy

NCT03574194
View directory record Official record
Conditions
Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Interventions
Methionine-restricted diet
Dietary Supplement
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Nov 7, 2026, 1:57 PM EST
Active, not recruiting Phase 1 Interventional

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

NCT06253520
View directory record Official record
Conditions
Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 7, 2026, 1:57 PM EST
Recruiting Not applicable Interventional

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

NCT06954337
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Usual practice pattern (UPP), Experimental: Enhanced Telehealth (ET)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 1:57 PM EST
Active, not recruiting Phase 1 Interventional

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339
View directory record Official record
Conditions
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions
NBTXR3, SABR, Nivolumab, Pembrolizumab
Drug · Radiation
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Nov 7, 2026, 1:57 PM EST
Recruiting Phase 1 Interventional

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

NCT04038619
View directory record Official record
Conditions
Colitis, Diarrhea, Malignant Genitourinary System Neoplasm, Melanoma, Lung Cancer, Ovarian Cancer, Uterine Cancer, Breast Cancer, Cervical Cancer
Interventions
Fecal Microbiota Transplantation, Loperamide
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 7, 2026, 1:57 PM EST
Terminated Phase 1 Interventional

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
NZV930, PDR001, NIR178
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Nov 7, 2026, 1:57 PM EST
Terminated No phase listed Observational

Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis

NCT00798187
View directory record Official record
Conditions
Prostate Cancer
Interventions
Group Meetings, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Nov 7, 2026, 1:57 PM EST
Completed Phase 2 Interventional

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

NCT05137067
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo, Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Dietary Supplement · Drug
Lead sponsor
Optimal Health Research
Other
Eligibility
25 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Nov 7, 2026, 1:57 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401
View directory record Official record
Conditions
Solid Tumors, CNS Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 7, 2026, 1:57 PM EST
Recruiting Not applicable Interventional

CONFIRM: Magnetic Resonance Guided Radiation Therapy

NCT04368702
View directory record Official record
Conditions
Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Interventions
Viewray MRIdian® Linac
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 7, 2026, 1:57 PM EST
Active, not recruiting Phase 1 Interventional

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144
View directory record Official record
Conditions
Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
17
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 7, 2026, 1:57 PM EST
Completed Phase 1 Interventional

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

NCT01234012
View directory record Official record
Conditions
Solid Tumor
Interventions
IMF-001
Biological
Lead sponsor
ImmunoFrontier, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Nov 7, 2026, 1:57 PM EST
Completed No phase listed Observational

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430
View directory record Official record
Conditions
Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 7, 2026, 1:57 PM EST
Completed Phase 1 Interventional

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00004095
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Nov 7, 2026, 1:57 PM EST
Completed Not applicable Interventional

An Intimacy Intervention for Couples Completing Breast or Prostate Cancer

NCT04221607
View directory record Official record
Conditions
Sexual Dysfunction, Breast Cancer, Prostate Cancer
Interventions
Sensate Focus exercise
Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 7, 2026, 1:57 PM EST
Active, not recruiting Not applicable Interventional

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

NCT05629065
View directory record Official record
Conditions
Breast Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Thoracic Cancer, Genitourinary Cancer
Interventions
Clinician Nudge Email, Patient Nudge Letter and Share questionaire
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Nov 7, 2026, 1:57 PM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

NCT04424641
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Nov 7, 2026, 1:57 PM EST